Modifies cell cycle by interfering with DNA structure and function. Effects are most prominent during the S phase but cells are killed at all stages. Cisplatin synergises with other anticancer drugs such as fluorouracil. Cisplatin has a narrow therapeutic margin and has high toxicity.
Metastatic testicular and ovarian carcinoma, advanced bladder cancers, refractory squamous cell neck and head carcinomas.
It is not effective after oral administration. It is given by intravenous route.
Renal impairment. Platinum hypersensitivity, hearing disorders.
Nausea, vomiting, fever, anaphylactic reactions, hypokalaemia, hypomagnesaemia, haemolysis, renal damage, sterility, teratogenesis, ototoxicity, peripheral neuropathy, raynaud's disease, bone marrow depression.
Hypocalcaemia, hypomagnesaemia, monitor neurological status, renal status and haematological function. Maintain hydration.
Initial half-life 25 - 49 mins, terminal elimination half-life 58 - 73 hours.
10mg
/ 20ml Injection,
|
||||||||||||||||||||||||||||||||||||||||
|
Disclaimer
: This guide is provided for information purposes only, and for use
of a registered medical practitioner or a hospital or a laboratory only.
The authors, webmaster, or respective references / links are no way
responsible for the content of the information. Although a concerted
effort has been made to ensure the validity of the information contained
in this document, we give no
assurance for the accuracy of the information in this documents. |